Claims for Patent: 10,450,365

Summary for Patent: 10,450,365

Title:	Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
Abstract:	Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
Inventor(s):	Grimm; Jan (Dubendorf, CH), Martin; Roland (Zurich, CH), Combaluzier; Benoit (Urdorf, CH), Jelcic; Ivan (Zurich, CH)
Assignee:	Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH)
Application Number:	15/678,965
Patent Claims:	1. A polynucleotide encoding at least a binding domain of a variable region of an immunoglobulin chain of a human monoclonal antibody or an antigen-binding fragment thereof capable of binding to a polyomavirus and/or antigen thereof, linked to a heterologous nucleic acid, wherein the polynucleotide is selected from the group consisting of: (a) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a V.sub.H variable region comprising CDRs 1, 2, and 3 of the V.sub.H variable region amino acid sequence of (i) SEQ ID NO: 2, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 binds to a polyomavirus and/or an antigen thereof; (ii) SEQ ID NO: 6, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 8 binds to a polyomavirus and/or an antigen thereof; (iii) SEQ ID NO: 10, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 12 binds to a polyomavirus and/or an antigen thereof; (iv) SEQ ID NO: 14, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 16 binds to a polyomavirus and/or an antigen thereof; (v) SEQ ID NO: 18, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 20 binds to a polyomavirus and/or an antigen thereof; (vi) SEQ ID NO: 22, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 24 binds to a polyomavirus and/or an antigen thereof; (vii) SEQ ID NO: 26, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 28 binds to a polyomavirus and/or an antigen thereof; (viii) SEQ ID NO: 30, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 32 binds to a polyomavirus and/or an antigen thereof; (ix) SEQ ID NO: 34, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 36 binds to a polyomavirus and/or an antigen thereof; (x) SEQ ID NO: 38, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 40 binds to a polyomavirus and/or an antigen thereof; (xi) SEQ ID NO: 42, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 44 binds to a polyomavirus and/or an antigen thereof; (xii) SEQ ID NO: 46, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 48 binds to a polyomavirus and/or an antigen thereof; (xiii) SEQ ID NO: 50, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 52 binds to a polyomavirus and/or an antigen thereof; (xiv) SEQ ID NO: 54, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 56 binds to a polyomavirus and/or an antigen thereof; (xv) SEQ ID NO: 58, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 60 binds to a polyomavirus and/or an antigen thereof; (xvi) SEQ ID NO: 62, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 64 binds to a polyomavirus and/or an antigen thereof; (xvii) SEQ ID NO: 66, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 68 binds to a polyomavirus and/or an antigen thereof; (xviii) SEQ ID NO: 70, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 72 binds to a polyomavirus and/or an antigen thereof; (xix) SEQ ID NO: 74, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 76 binds to a polyomavirus and/or an antigen thereof; (xx) SEQ ID NO: 78, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 80 binds to a polyomavirus and/or an antigen thereof; (xxi) SEQ ID NO: 82, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 84 binds to a polyomavirus and/or an antigen thereof; (xxii) SEQ ID NO: 90, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 92 binds to a polyomavirus and/or an antigen thereof; (xxiii) SEQ ID NO: 94, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 96 binds to a polyomavirus and/or an antigen thereof; (xxiv) SEQ ID NO: 98, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 100 binds to a polyomavirus and/or an antigen thereof; (xxv) SEQ ID NO: 102, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 104 binds to a polyomavirus and/or an antigen thereof; (xxvi) SEQ ID NO: 106, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 108 binds to a polyomavirus and/or an antigen thereof; (xxvii) SEQ ID NO: 114, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 116 binds to a polyomavirus and/or an antigen thereof; (xxviii) SEQ ID NO: 118, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 120 binds to a polyomavirus and/or an antigen thereof; (xxxix) SEQ ID NO: 122, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 124 binds to a polyomavirus and/or an antigen thereof; (xxx) SEQ ID NO: 126, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 128 binds to a polyomavirus and/or an antigen thereof; (xxxi) SEQ ID NO: 130, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 132 binds to a polyomavirus and/or an antigen thereof; (xxxii) SEQ ID NO: 134, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 136 binds to a polyomavirus and/or an antigen thereof; (xxxiii) SEQ ID NO: 138, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 140 binds to a polyomavirus and/or an antigen thereof; (xxxiv) SEQ ID NO: 142, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 144 binds to a polyomavirus and/or an antigen thereof; (xxxv) SEQ ID NO: 146, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 148 binds to a polyomavirus and/or an antigen thereof; (xxxvi) SEQ ID NO: 150, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 152 binds to a polyomavirus and/or an antigen thereof; (xxxvii) SEQ ID NO: 154, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 156 binds to a polyomavirus and/or an antigen thereof; (xxxviii) SEQ ID NO: 158, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 160 binds to a polyomavirus and/or an antigen thereof; (xxxix) SEQ ID NO: 162, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 164 binds to a polyomavirus and/or an antigen thereof; or (xl) SEQ ID NO: 166, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 168 binds to a polyomavirus and/or an antigen thereof; (b) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a V.sub.L variable region comprising CDRs 1, 2, and 3 of the V.sub.L variable region amino acid sequence of (i) SEQ ID NO: 4, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 2 binds to a polyomavirus and/or an antigen thereof; (ii) SEQ ED NO: 8, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 binds to a polyomavirus and/or an antigen thereof; (iii) SEQ ID NO: 12, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 10 binds to a polyomavirus and/or an antigen thereof; (iv) SEQ ID NO: 16, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 14 binds to a polyomavirus and/or an antigen thereof; (v) SEQ ID NO: 20, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 18 binds to a polyomavirus and/or an antigen thereof; (vi) SEQ ID NO: 24, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 22 binds to a polyomavirus and/or an antigen thereof; (vii) SEQ ID NO: 28, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 26 binds to a polyomavirus and/or an antigen thereof; (viii) SEQ ID NO: 32, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 30 binds to a polyomavirus and/or an antigen thereof; (ix) SEQ ID NO: 36, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 34 binds to a polyomavirus and/or an antigen thereof; (x) SEQ ID NO: 40, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 38 binds to a polyomavirus and/or an antigen thereof; (xi) SEQ ID NO: 44, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 42 binds to a polyomavirus and/or an antigen thereof; (xii) SEQ ID NO: 48, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 46 binds to a polyomavirus and/or an antigen thereof; # (xiii) SEQ ID NO: 52, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 50 binds to a polyomavirus and/or an antigen thereof; (xiv) SEQ ID NO: 56, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 54 binds to a polyomavirus and/or an antigen thereof; (xv) SEQ ID NO: 60, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 58 binds to a polyomavirus and/or an antigen thereof; (xvi) SEQ ID NO: 64, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 62 binds to a polyomavirus and/or an antigen thereof; (xvii) SEQ ID NO: 68, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 66 binds to a polyomavirus and/or an antigen thereof; (xviii) SEQ ID NO: 72, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 70 binds to a polyomavirus and/or an antigen thereof; (xix) SEQ ID NO: 76, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 74 binds to a polyomavirus and/or an antigen thereof; (xx) SEQ ID NO: 80, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 78 binds to a polyomavirus and/or an antigen thereof; (xxi) SEQ ID NO: 84, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 82 binds to a polyomavirus and/or an antigen thereof; (xxii) SEQ ID NO: 92, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 90 binds to a polyomavirus and/or an antigen thereof; (xxiii) SEQ ID NO: 96, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 94 binds to a polyomavirus and/or an antigen thereof; (xxiv) SEQ ID NO: 100, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 98 binds to a polyomavirus and/or an antigen thereof; (xxv) SEQ ID NO: 104, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 102 binds to a polyomavirus and/or an antigen thereof; (xxvi) SEQ ID NO: 108, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 106 binds to a polyomavirus and/or an antigen thereof; (xxvii) SEQ ID NO: 116, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 114 binds to a polyomavirus and/or an antigen thereof; (xxviii) SEQ ID NO: 120, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 118 binds to a polyomavirus and/or an antigen thereof; (xxix) SEQ ID NO: 124, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 122 binds to a polyomavirus and/or an antigen thereof; (xxx) SEQ ID NO: 128, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 126 binds to a polyomavirus and/or an antigen thereof; (xxxi) SEQ ID NO: 132, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 130 binds to a polyomavirus and/or an antigen thereof; (xxxii) SEQ ID NO: 136, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 134 binds to a polyomavirus and/or an antigen thereof; (xxxiii) SEQ ID NO: 140, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 138 binds to a polyomavirus and/or an antigen thereof; (xxxiv) SEQ ID NO: 144, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 142 binds to a polyomavirus and/or an antigen thereof; (xxxv) SEQ ID NO: 148, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 146 binds to a polyomavirus and/or an antigen thereof; (xxxvi) SEQ ID NO: 152, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 150 binds to a polyomavirus and/or an antigen thereof; (xxxvii) SEQ ID NO: 156, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 154 binds to a polyomavirus and/or an antigen thereof; (xxxviii) SEQ ID NO: 160, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 158 binds to a polyomavirus and/or an antigen thereof; (xxxix) SEQ ID NO: 164, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 162 binds to a polyomavirus and/or an antigen thereof; or (xl) SEQ ID NO: 168, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 166 binds to a polyomavirus and/or an antigen thereof; (c) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a V.sub.H variable region and an immunoglobulin light chain or a fragment thereof comprising a V.sub.L variable region comprising CDRs 1, 2, and 3 of the V.sub.H and V.sub.L variable region amino acid sequences of (i) SEQ ID NO: 2 and SEQ ID NO: 4, respectively; (ii) SEQ ID No: 6 and SEQ NO: 8, respectively; (iii) SEQ ID No: 10 and SEQ NO: 12, respectively; (iv) SEQ ID No: 14 and SEQ NO: 16, respectively; (v) SEQ ID No: 18 and SEQ NO: 20, respectively; (vi) SEQ ID No: 22 and SEQ NO: 24, respectively; (vii) SEQ ID No: 26 and SEQ NO: 28, respectively; (viii) SEQ ID No: 30 and SEQ NO: 32, respectively; (ix) SEQ ID No: 34 and SEQ NO: 36, respectively; (x) SEQ ID No: 38 and SEQ NO: 40, respectively; (xi) SEQ ID No: 42 and SEQ NO: 44, respectively; (xii) SEQ ID No: 46 and SEQ NO: 48, respectively; (xiii) SEQ ID No: 50 and SEQ NO: 52, respectively; (xiv) SEQ ID No: 54 and SEQ NO: 56, respectively; (xv) SEQ ID No: 58 and SEQ NO: 60, respectively; (xvi) SEQ ID No: 62 and SEQ NO: 64, respectively; (xvii) SEQ ID No: 66 and SEQ NO: 68, respectively; (xviii) SEQ ID No: 70 and SEQ NO: 72, respectively; (xix) SEQ ID No: 74 and SEQ NO: 76, respectively; (xx) SEQ ID No: 78 and SEQ NO: 80, respectively; (xxi) SEQ ID No: 82 and SEQ NO: 84, respectively; (xxii) SEQ ID No: 90 and SEQ NO: 92, respectively; (xxiii) SEQ ID No: 94 and SEQ NO: 96, respectively; (xxiv) SEQ ID No: 98 and SEQ NO: 100, respectively; (xxv) SEQ ID No: 102 and SEQ NO: 104, respectively; (xxvi) SEQ ID No: 106 and SEQ NO: 108, respectively; (xxvii) SEQ ID No: 114 and SEQ NO: 116, respectively; (xxviii) SEQ ID No: 118 and SEQ NO: 120, respectively; (xxix) SEQ ID No: 122 and SEQ NO: 124, respectively; (xxx) SEQ ID No: 126 and SEQ NO: 128, respectively; (xxxi) SEQ ID No: 130 and SEQ NO: 132, respectively; (xxxii) SEQ ID No: 134 and SEQ NO: 136, respectively; (xxxiii) SEQ ID No: 138 and SEQ NO: 140, respectively; (xxxiv) SEQ ID No: 142 and SEQ NO: 144, respectively; (xxxv) SEQ ID No: 146 and SEQ NO: 148, respectively; (xxxvi) SEQ ID No: 150 and SEQ NO: 152, respectively; (xxxvii) SEQ ID No: 154 and SEQ NO:156, respectively; (xxxviii) SEQ ID No: 158 and SEQ NO: 160, respectively; (xxxix) SEQ ID No: 162 and SEQ NO: 164, respectively; or (xl) SEQ ID No: 166 and SEQ NO: 168, respectively; (d) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a V.sub.H variable region comprising the amino acid sequence set forth in (i) SEQ ID NO: 2, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 binds to a polyomavirus and/or an antigen thereof; (ii) SEQ ID No. 6, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 8 binds to a polyomavirus and/or an antigen thereof; (iii) SEQ ID No. 10, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 12 binds to a polyomavirus and/or an antigen thereof; (iv) SEQ ID No. 14, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 16 binds to a polyomavirus and/or an antigen thereof; (v) SEQ ID No. 18, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ IT) NO: 20 binds to a polyomavirus and/or an antigen thereof; (vi) SEQ ID No. 22, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 24 binds to a polyomavirus and/or an antigen thereof; (vii) SEQ ID No. 26, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 28 binds to a polyomavirus and/or an antigen thereof; (viii) SEQ ID No. 30, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 32 binds to a polyomavirus and/or an antigen thereof; (ix) SEQ ID No. 34, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 36 binds to a polyomavirus and/or an antigen thereof; (x) SEQ ID No. 38, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 40 binds to a polyomavirus and/or an antigen thereof; (xi) SEQ ID No. 42, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 44 binds to a polyomavirus and/or an antigen thereof; (xii) SEQ ID No. 46, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 48 binds to a polyomavirus and/or an antigen thereof; (xiii) SEQ ID No. 50, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 52 binds to a polyomavirus and/or an antigen thereof; (xiv) SEQ ID No. 54, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 56 binds to a polyomavirus and/or an antigen thereof; (xv) SEQ ID No. 58, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 60 binds to a polyomavirus and/or an antigen thereof; (xvi) SEQ ID No. 62, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 64 binds to a polyomavirus and/or an antigen thereof; (xvii) SEQ ID No. 66, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 68 binds to a polyomavirus and/or an antigen thereof; (xviii) SEQ ID No. 70, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 72 binds to a polyomavirus and/or an antigen thereof; (xix) SEQ ID No. 74, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 76 binds to a polyomavirus and/or an antigen thereof; (xx) SEQ ID No. 78, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 80 binds to a polyomavirus and/or an antigen thereof; (xxi) SEQ ID No. 82, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 84 binds to a polyomavirus and/or an antigen thereof; (xxii) SEQ ID No. 90, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 92 binds to a polyomavirus and/or an antigen thereof; (xxiii) SEQ ID No. 94, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 96 binds to a polyomavirus and/or an antigen thereof; (xxiv) SEQ ID No. 98, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ TD NO: 100 binds to a polyomavirus and/or an antigen thereof; (xxv) SEQ ID No. 102, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 104 binds to a polyomavirus and/or an antigen thereof; (xxvi) SEQ ID No. 106, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 108 binds to a polyomavirus and/or an antigen thereof; (xxvii) SEQ ID No. 114, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 116 binds to a polyomavirus and/or an antigen thereof; (xxviii) SEQ ID No. 118, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 120 binds to a polyomavirus and/or an antigen thereof; (xxix) SEQ ID No. 122, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 124 binds to a polyomavirus and/or an antigen thereof; (xxx) SEQ ID No. 126, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 128 binds to a polyomavirus and/or an antigen thereof; (xxxi) SEQ ID No. 130, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 132 binds to a polyomavirus and/or an antigen thereof; (xxxii) SEQ ID No. 134, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 136 binds to a polyomavirus and/or an antigen thereof; (xxxiii) SEQ ID No. 138, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 140 binds to a polyomavirus and/or an antigen thereof; (xxxiv) SEQ ID No. 142, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 144 binds to a polyomavirus and/or an antigen thereof; (xxxv) SEQ ID No. 146, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 148 binds to a polyomavirus and/or an antigen thereof; (xxxvi) SEQ ID No. 150, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 152 binds to a polyomavirus and/or an antigen thereof; (xxxvii) SEQ ID No. 154, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 156 binds to a polyomavirus and/or an antigen thereof; (xxxviii) SEQ ID No. 158, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 160 binds to a polyomavirus and/or an antigen thereof; (xxxix) SEQ ID No. 162, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 164 binds to a polyomavirus and/or an antigen thereof; or (xl) SEQ ID No. 166, wherein the V.sub.H variable region when paired with a V.sub.L variable region comprising the amino acid sequence set forth in SEQ ID NO: 168 binds to a polyomavirus and/or an antigen thereof; (e) a polynucleotide encoding an immunoglobulin light chain or a fragment thereof comprising a V.sub.L variable region comprising the amino acid sequence set forth in (i) SEQ ID NO: 4, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 2, binds to a polyomavirus and/or an antigen thereof; and (ii) SEQ ID NO: 8, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 binds to a polyomavirus and/or an antigen thereof; (iii) SEQ ID NO: 12, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 10 binds to a polyomavirus and/or an antigen thereof; (iv) SEQ ID NO: 16, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 14 binds to a polyomavirus and/or an antigen thereof; (v) SEQ ID NO: 20, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 18 binds to a polyomavirus and/or an antigen thereof; (vi) SEQ ID NO: 24, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 22 binds to a polyomavirus and/or an antigen thereof; (vii) SEQ ID NO: 28, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 26 binds to a polyomavirus and/or an antigen thereof; (viii) SEQ ID NO: 32, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 30 binds to a polyomavirus and/or an antigen thereof; (ix) SEQ ID NO: 36, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 34 binds to a polyomavirus and/or an antigen thereof; (x) SEQ ID NO: 40, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 38 binds to a polyomavirus and/or an antigen thereof; (xi) SEQ ID NO: 44, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 42 binds to a polyomavirus and/or an antigen thereof; (xii) SEQ ID NO: 48, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 46 binds to a polyomavirus and/or an antigen thereof; (xiii) SEQ ID NO: 52, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 50 binds to a polyomavirus and/or an antigen thereof; (xiv) SEQ ID NO: 56, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 54 binds to a polyomavirus and/or an antigen thereof; (xv) SEQ ID NO: 60, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 58 binds to a polyomavirus and/or an antigen thereof; (xvi) SEQ ID NO: 64, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 62 binds to a polyomavirus and/or an antigen thereof; (xvii) SEQ ID NO: 68, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 66 binds to a polyomavirus and/or an antigen thereof; (xviii) SEQ ID NO: 72, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 70 binds to a polvomavirus and/or an antigen thereof; (xix) SEQ ID NO: 76, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 74 binds to a polyomavirus and/or an antigen thereof; (xx) SEQ ID NO: 80, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 78 binds to a polyomavirus and/or an antigen thereof; (xxi) SEQ ID NO: 84, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 82 binds to a polyomavirus and/or an antigen thereof; (xxii) SEQ ID NO: 92, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 90 binds to a polyomavirus and/or an antigen thereof; (xxvii) SEQ ID NO: 96, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 94 binds to a polyomavirus and/or an antigen thereof; (xxiv) SEQ ID NO: 100, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 98 binds to a polyomavirus and/or an antigen thereof; (xxv) SEQ ID NO: 104, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 102 binds to a polyomavirus and/or an antigen thereof; (xxvi) SEQ ID NO: 108, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 106 binds to a polyomavirus and/or an antigen thereof; (xxvii) SEQ ID NO: 116, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 114 binds to a polyomavirus and/or an antigen thereof; (xxviii) SEQ ID NO: 120, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 118 binds to a polyomavirus and/or an antigen thereof; (xxix) SEQ ID NO: 124, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 122 binds to a polyomavirus and/or an antigen thereof; (xxx) SEQ ID NO: 128, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 126 binds to a polyomavirus and/or an antigen thereof; (xxxi) SEQ ID NO: 132, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 130 binds to a polyomavirus and/or an antigen thereof; (xxxii) SEQ ID NO: 136, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 134 binds to a polyomavirus and/or an antigen thereof; (xxxiii) SEQ ID NO: 140, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 138 binds to a polyomavirus and/or an antigen thereof; (xxxiv) SEQ ID NO: 144, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 142 binds to a polyomavirus and/or an antigen thereof; (xxxv) SEQ ID NO: 148, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 146 binds to a polyomavirus and/or an antigen thereof; (xxxvi) SEQ ID NO: 152, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 150 binds to a polyomavirus and/or an antigen thereof; (xxxvii) SEQ ID NO: 156, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 154 binds to a polyomavirus and/or an antigen thereof; (xxxviii) SEQ ID NO: 160, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 158 binds to a polyomavirus and/or an antigen thereof; (xxxix) SEQ ID NO: 164, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 162 binds to a polyomavirus and/or an antigen thereof; or (xl) SEQ ID NO: 168, wherein the V.sub.L variable region when paired with a V.sub.H variable region comprising the amino acid sequence set forth in SEQ ID NO: 166 binds to a polyomavirus and/or an antigen thereof; (f) a polynucleotide encoding an immunoglobulin heavy chain or a fragment thereof comprising a V.sub.H variable region and an immunoglobulin light chain or a fragment thereof comprising a V.sub.L variable region comprising the amino acid sequences set forth in (i) SEQ ID NO: 2 and 4, respectively; (ii) SEQ ID NO: 6 and 8, respectively; (iii) SEQ ID NO: 10 and 12, respectively; (iv) SEQ ID NO: 14 and 16, respectively; (v) SEQ ID NO: 18 and 20, respectively; (vi) SEQ ID NO: 22 and 24, respectively; (vii) SEQ ID NO: 26 and 28, respectively; (viii) SEQ ID NO: 30 and 32, respectively; (ix) SEQ ID NO: 34 and 36, respectively; (x) SEQ ID NO: 38 and 40, respectively; (xi) SEQ ID NO: 42 and 44, respectively; (xii) SEQ ID NO: 46 and 48, respectively; (xiii) SEQ ID NO: 50 and 52, respectively; (xiv) SEQ ID NO: 54 and 56, respectively; (xv) SEQ ID NO: 58 and 60, respectively; (xvi) SEQ ID NO: 62 and 64, respectively; (xvii) SEQ ID NO: 66 and 68, respectively; (xviii) SEQ ID NO: 70 and 72, respectively; (xix) SEQ ID NO: 74 and 76, respectively; (xx) SEQ ID NO: 78 and 80, respectively; (xxi) SEQ ID NO: 82 and 84, respectively; (xxii) SEQ ID NO: 90 and 92, respectively; (xxiii) SEQ ID NO: 94 and 96, respectively; (xxiv) SEQ ID NO: 98 and 100, respectively; (xxv) SEQ ID NO: 102 and 104, respectively; (xxvi) SEQ ID NO: 106 and 108, respectively; (xxvii) SEQ ID NO: 114 and 116, respectively; (xxviii) SEQ ID NO: 118 and 120, respectively; (xxix) SEQ ID NO: 122 and 124, respectively; (xxx) SEQ ID NO: 126 and 128, respectively; (xxxi) SEQ ID NO: 130 and 132, respectively; (xxxii) SEQ ID NO: 134 and 136, respectively; (xxxiii) SEQ ID NO: 138 and 140, respectively; (xxxiv) SEQ ID NO: 142 and 144, respectively; (xxxv) SEQ ID NO: 146 and 148, respectively; (xxxvi) SEQ ID NO: 150 and 152, respectively; (xxxvii) SEQ ID NO: 154 and 156, respectively; (xxxviii) SEQ ID NO: 158 and 160, respectively; (xxxix) SEQ ID NO: 162 and 164, respectively; or (xl) SEQ ID NO: 166 and 168, respectively. 2. One or more vector(s) comprising one or more polynucleotide(s) of claim 1. 3. The vector(s) of claim 2, further comprising a polynucleotide encoding at least a binding domain of a variable region of an immunoglobulin chain of a human monoclonal antibody or an antigen-binding fragment thereof capable of binding to a polyomavirus and/or antigen thereof, wherein the polyomavirus is JC virus (JCV) or BK virus (BKV), wherein the polynucleotide further encodes the variable region of the other immunoglobulin chain of the antibody or an antigen-binding fragment thereof. 4. An isolated host cell comprising one or more polynucleotide(s) of claim 1. 5. A composition comprising a polynucleotide of claim 1. 6. The composition of claim 5, wherein the composition: (a) is a pharmaceutical composition and further comprises a pharmaceutical acceptable carrier, or (b) is a diagnostic composition, and further comprises reagents conventionally used in immune- or nucleic acid based diagnostic methods. 7. The composition of claim 5, further comprising an immunomodulatory agent. 8. A kit useful in the diagnosis or monitoring of the progression of Progressive Multifocal Leukoencephalopathy (PML) and/or transplant rejection following clinical bone marrow, kidney, and other solid organs transplantations, said kit comprising the antibody or an antigen-binding fragment thereof encoded by the polynucleotide of claim 1. 9. The kit of claim 8, further comprising reagents and/or instructions for use. 10. The composition of claim 6, wherein the pharmaceutical composition is used for the prophylactic or therapeutic treatment of a disease, the disease is Progressive Multifocal Leukoencephalopathy (PML), infection of granule neurons, hyperchromatic nuclei, granule cell neuronopathy, cerebral autothrophy, encephalopathy, meningitis, Polyoma-induced tumors, immune reconstitution inflammatory syndrome (IRIS), hemorrhagic cystitis, pneumonia, retinitis, colitis, vasculitis, interstitial kidney disease, infections of respiratory tract, JCV nephropathy, BKV nephropathy, meningitis, Merkel cell carcinoma, trichodysplasia spinulosa, or malignant pleural mesothelioma. 11. A complementary DNA (cDNA) molecule encoding at least a binding domain of a variable region of an immunoglobulin chain of an antibody or antigen binding fragment thereof, wherein the antibody or antigen-binding fragment thereof is capable of binding to a polyomavirus or an antigen thereof, wherein the antibody or antigen-binding fragment thereof comprises in its variable region: (a) the complementarity determining regions (CDRs) 1, 2, and 3 of: (i) the V.sub.H variable region amino acid sequence of SEQ ID NO: 2 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 4; (ii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 6 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 8; (iii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 10 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 12; (iv) the V.sub.H variable region amino acid sequence of SEQ ID NO: 14 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 16; (v) the V.sub.H variable region amino acid sequence of SEQ ID NO: 18 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 20; (vi) the V.sub.H variable region amino acid sequence of SEQ ID NO: 22 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 24; (vii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 26 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 28; (viii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 30 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 32; (ix) the V.sub.H variable region amino acid sequence of SEQ ID NO: 34 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 36; (x) the V.sub.H variable region amino acid sequence of SEQ ID NO: 38 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 40; (xi) the V.sub.H variable region amino acid sequence of SEQ ID NO: 42 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 44; (xii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 46 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 48; (xiii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 50 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 52; (xiv) the V.sub.H variable region amino acid sequence of SEQ ID NO: 54 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 56; (xv) the V.sub.H variable region amino acid sequence of SEQ ID NO: 58 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 60; (xvi) the V.sub.H variable region amino acid sequence of SEQ ID NO: 62 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 64; (xvii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 66 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 68; (xviii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 70 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 72; (xix) the V.sub.H variable region amino acid sequence of SEQ ID NO: 74 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 76; (xx) the V.sub.H variable region amino acid sequence of SEQ ID NO: 78 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 80; (xxi) the V.sub.H variable region amino acid sequence of SEQ ID NO: 82 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 84; (xxii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 90 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 92; (xxiii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 94 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 96; (xxiv) the V.sub.H variable region amino acid sequence of SEQ ID NO: 98 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 100; (xxv) the V.sub.H variable region amino acid sequence of SEQ ID NO: 102 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 104; (xxvi) the V.sub.H variable region amino acid sequence of SEQ ID NO: 106 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 108; (xxvii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 114 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 116; (xxviii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 118 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 120; (xxix) the V.sub.H variable region amino acid sequence of SEQ ID NO: 122 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 124; (xxx) the V.sub.H variable region amino acid sequence of SEQ ID NO: 126 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 128; (xxxi) the V.sub.H variable region amino acid sequence of SEQ ID NO: 130 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 132; (xxxii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 134 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 136; (xxxiii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 138 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 140; (xxxiv) the V.sub.H variable region amino acid sequence of SEQ ID NO: 142 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 144; (xxxv) the V.sub.H variable region amino acid sequence of SEQ ID NO: 146 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 148; (xxxvi) the V.sub.H variable region amino acid sequence of SEQ ID NO: 150 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 152; (xxxvii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 154 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 156; (xxxviii) the V.sub.H variable region amino acid sequence of SEQ ID NO: 158 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 160; (xxxix) the V.sub.H variable region amino acid sequence of SEQ ID NO: 162 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 164; or (xl) the V.sub.H variable region amino acid sequence of SEQ ID NO: 166 and the V.sub.L variable region amino acid sequence of SEQ ID NO: 168; or (b) (i) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 2, and the V.sub.L variable region set forth in SEQ ID NO: 4; (ii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 6 and the V.sub.L variable region set forth in SEQ ID NO: 8; (iii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 10 and the V.sub.L variable region set forth in SEQ ID NO: 12; (iv) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 14 and the V.sub.L variable region set forth in SEQ ID NO: 16; (v) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 18 and the V.sub.L variable region set forth in SEQ ID NO: 20; (vi) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 22 and the V.sub.L variable region set forth in SEQ ID NO: 24; (vii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 26 and the V.sub.L variable region set forth in SEQ ID NO: 28; (viii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 30 and the V.sub.L variable region set forth in SEQ ID NO: 32; (ix) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 34 and the V.sub.L variable region set forth in SEQ ID NO: 36; (x) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 38 and the V.sub.L variable region set forth in SEQ ID NO: 40; (xi) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 42 and the V.sub.L variable region set forth in SEQ NO: 44; (xii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 46 and the V.sub.L variable region set forth in SEQ ID NO: 48; (xiii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 50 and the V.sub.L variable region set forth in SEQ ID NO: 52; (xiv) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 54 and the V.sub.L variable region set forth in SEQ ID NO: 56; (xv) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 58 and the V.sub.L variable region set forth in SEQ ID NO: 60; (xvi) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 62 and the V.sub.L variable region set forth in SEQ ID NO: 64; (xvii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 66 and the V.sub.L variable region set forth in SEQ ID NO: 68; (xviii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 70 and the V.sub.L variable region set forth in SEQ ID NO: 72; (xix) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 74 and the V.sub.L variable region set forth in SEQ ID NO: 76; (xx) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 78 and the V.sub.L variable region set forth in SEQ ID NO: 80; (xxi) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 82 and the V.sub.L variable region set forth in SEQ ID NO: 84; (xxii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 90 and the V.sub.L variable region set forth in SEQ ID NO: 92; (xxiii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 94 and the V.sub.L variable region set forth in SEQ ID NO: 96; (xxiv) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 98 and the V.sub.L variable region set forth in SEQ ID NO: 100; (xxv) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 102 and the V.sub.L variable region set forth in SEQ ID NO: 104; (xxvi) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 106 and the V.sub.L variable region set forth in SEQ ID NO: 108; (xxvii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 114 and the V.sub.L variable region set forth in SEQ ID NO: 116; (xxviii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 118 and the V.sub.L variable region set forth in SEQ ID NO: 120; (xxix) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 122 and the V.sub.L variable region set forth in SEQ ID NO: 124; (xxx) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 126 and the V.sub.L variable region set forth in SEQ ID NO: 128; (xxxi) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 130 and the V.sub.L variable region set forth in SEQ ID NO: 132; (xxxii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 134 and the V.sub.L variable region set forth in SEQ ID NO: 136; (xxxiii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 138 and the V.sub.L variable region set forth in SEQ ID NO: 140; (xxxiv) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 142 and the V.sub.L variable region set forth in SEQ ID NO: 144; (xxxv) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 146 and the V.sub.L variable region set forth in SEQ ID NO: 148; (xxxvi) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 150 and the V.sub.L variable region set forth in SEQ ID NO: 152; (xxxvii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 154 and the V.sub.L variable region set forth in SEQ ID NO: 156; (xxxviii) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 158 and the V.sub.L variable region set forth in SEQ ID NO: 160; (xxxix) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 162 and the V.sub.L variable region set forth in SEQ ID NO: 164; or (xl) an amino acid sequence of the V.sub.H variable region set forth in SEQ ID NO: 166 and the V.sub.L variable region set forth in SEQ ID NO: 168. 12. A vector comprising the cDNA of claim 11, encoding the variable region of the other immunoglobulin chain of the antibody or an antigen-binding fragment thereof. 13. The polynucleotide of claim 1, wherein the polyomavirus is JC virus (JCV) or BK virus (BKV). 14. The polynucleotide of claim 1, wherein the antibody or antigen-binding fragment thereof is capable of binding VP1 protein or a fragment thereof. 15. The polynucleotide of claim 1, wherein the antibody or antigen-binding fragment thereof is capable of recognizing an epitope exposed on the surface of the virus. 16. The polynucleotide of claim 1, wherein the antibody or antigen-binding fragment thereof does not substantially recognize serum albumin. 17. The polynucleotide of claim 16, wherein the serum albumin is bovine serum albumin (BSA). 18. The polynucleotide of claim 1, wherein the antibody or antigen-binding fragment thereof recognizes progressive multifocal leukoencephalopathy (PML)-associated VP1 mutants. 19. The vector(s) of claim 2 or 12, which is or are (an) expression vector(s). 20. An isolated host cell comprising one or more vector(s) of claim 19. 21. The composition of claim 7, wherein the agent is natalizumab, efalizumab, rituximab, infliximab, ocrelizumab, alemtuzumab, bentuximab, or vedotin.

Details for Patent 10,450,365

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2032-12-31
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2032-12-31
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2032-12-31
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2032-12-31